Established in 2014, we are a reputable AI-driven biotech company with Business all over the world. Our clinical-stage assets currently include an asset in phase II clinical stage, which is at a relatively advanced stage in the industry. As of the last practical date, we have generated more than 20 clinical or IND reporting assets through our self-developed generative artificial intelligence platform Pharma.ai. Three of these assets have been authorized to international pharmaceutical and healthcare companies, with a total contract value of over 2 billion US dollars. We operate on a project-based business model. Our main source of revenue is external licensing and cooperative arrangements, but we cannot guarantee or clearly predict future revenue generation. On average, our drug candidates take 12 to 18 months from target discovery to pre-clinical drug candidate confirmation, which is far shorter than traditional methods (an average time of 4.5 years). Our unique twin-engine business model combines a generative AI platform with deep independent drug development capabilities to achieve continuous reinforcement learning, continuously improve Pharma.AI's capabilities, and promote scientific innovation. We are also expanding the scope of application of Pharma.ai to various Industry, such as advanced materials, agriculture, nutritional products, and veterinary pharmaceuticals.